BioNTech Se

The momentum for this stock is not very good. BioNTech Se is not a good growth stock. BioNTech Se is not very popular among insiders. BioNTech Se is a mediocre stock to choose.

News

BioNTech Breaks Above 200-Day Moving Average - Bullish for BNTX

Market News Video In trading on Monday, shares of BioNTech SE (BNTX) crossed above their 200 day moving average of 92.56, changing hands as high as 94.86 per share. BioNTech SE shares are currently trading...\n more…

BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024

Globe Newswire MAINZ, Germany, September 05, 2024 BioNTech SE (Nasdaq: BNTX, BioNTech or the Company ) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the...\n more…

Tempus Announces Real World Data Collaboration with BioNTech

Business Wire Tempus AI, Inc. (NASDAQ: TEM, Tempus), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a multi-year collaboration with BioNTech SE...\n more…

BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 388 Shares of BioNTech SE (NASDAQ:BNTX)

Ticker Report BNP PARIBAS ASSET MANAGEMENT Holding S.A. cut its holdings in BioNTech SE (NASDAQ:BNTX - Free Report) by 4.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and...\n more…

BioNTech SE (NASDAQ:BNTX) Expected to Post FY2024 Earnings of ($3.71) Per Share

Ticker Report BioNTech SE (NASDAQ:BNTX - Free Report) - Equities researchers at HC Wainwright dropped their FY2024 earnings per share estimates for BioNTech in a research note issued on Tuesday, August 27th. HC...\n more…

HC Wainwright Equities Analysts Reduce Earnings Estimates for BioNTech SE (NASDAQ:BNTX)

Zolmax BioNTech SE (NASDAQ:BNTX - Free Report) - Equities researchers at HC Wainwright reduced their FY2024 EPS estimates for shares of BioNTech in a research note issued on Tuesday, August 27th. HC...\n more…